What's Happening?
Advanced NanoTherapies, Inc., a clinical-stage medtech company, has closed a Series B financing round, raising over $31 million to support the development of its dual-drug nanoparticle-coated balloon platform for vascular treatment. The funding will enable
the company to advance its U.S. Investigational Device Exemption (IDE) submissions and expand its coronary and peripheral artery disease programs. The platform, known as SirPlux Duo, combines paclitaxel and sirolimus to deliver therapeutic effects with sustained vascular response. The technology is licensed from Cleveland Clinic and aims to address clinical challenges such as restenosis after percutaneous coronary intervention (PCI).
Why It's Important?
The successful Series B funding round positions Advanced NanoTherapies to significantly impact the field of vascular intervention. By developing a dual-drug delivery system, the company addresses limitations of existing single-drug coated balloons, potentially improving patient outcomes in coronary and peripheral artery disease treatments. The funding will support regulatory submissions and clinical trials, paving the way for commercialization and broader adoption of the technology. This advancement could lead to more effective and predictable vascular therapies, benefiting patients and healthcare providers.
What's Next?
Advanced NanoTherapies plans to scale up manufacturing to meet FDA IDE requirements and advance its coronary and peripheral programs. The company will focus on completing testing packages and IDE submissions for U.S. clinical trials, including a pivotal trial agreement with the FDA. Identifying clinical sites outside the U.S. for early pivotal enrollment centers is also a priority. These steps will facilitate the progression of SirPlux Duo towards commercialization, potentially transforming vascular treatment paradigms.
